Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:dateCreated |
1996-9-17
|
pubmed:abstractText |
Interleukin 12 (IL-12) is a heterodimeric cytokine with a number of biological effects that are consistent with its potential role as an antitumor agent. The antimetastatic and antitumor activities of IL-12 have been demonstrated in a number of murine tumor models. Both the inhibition of established experimental pulmonary or hepatic metastases and a reduction in spontaneous metastases have been achieved by treatment with murine IL-12. Systemic treatment of mice bearing subcutaneous tumors with IL-12 results in tumor growth inhibition, prolongation of survival, and, in some models, tumor regression. The antitumor effect of IL-12 in these models is dose-dependent and can be initiated against well-established tumors. Mice cured of their tumor by IL-12 treatment are specifically immune to rechallenge with the same tumor. A series of experiments have demonstrated that both T-cells and interferon-gamma (IFN-gamma) induction are necessary for the optimal antitumor effects of IL-12. However, the antitumor efficacy of IL-12 has not been observed after exogenous administration of murine IFN-gamma, suggesting that additional factors may be important for the antitumor effects of IL-12. In several tumor models, IL-12 is more active or has a larger therapeutic window than either IL-2 or IFN-alpha, two cytokines with demonstrated antitumor activity against human malignancies. Combining IL-12 with other cytokines or chemotherapeutic drugs can improve antitumor effects.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:issn |
0344-5704
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
38 Suppl
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
S16-21
|
pubmed:dateRevised |
2005-11-16
|
pubmed:meshHeading |
pubmed-meshheading:8765410-Animals,
pubmed-meshheading:8765410-Drug Screening Assays, Antitumor,
pubmed-meshheading:8765410-Humans,
pubmed-meshheading:8765410-Interleukin-12,
pubmed-meshheading:8765410-Interleukin-2,
pubmed-meshheading:8765410-Neoplasms, Experimental,
pubmed-meshheading:8765410-Tumor Cells, Cultured
|
pubmed:year |
1996
|
pubmed:articleTitle |
Antitumor activity of interleukin 12 in preclinical models.
|
pubmed:affiliation |
Department of Oncology, Hoffmann-La Roche Inc., Nutley, NJ 07110, USA.
|
pubmed:publicationType |
Journal Article,
Review
|